EMA: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2020
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of safety signals, risk management plans, periodic safety update reports and post-authorisation safety studies.
The Committee did not start or conclude any referral procedures. More information on all safety reviews currently under evaluation is provided in the ‘Ongoing referrals’ table.
Posted on the EMA website on 10 July 2020